Tuesday, December 8, 2015

NEW DELHI - Hetero gets DCGI approval to market Gilead's Harvoni Hepatitis C drug

Hetero gets DCGI approval to market Hepatitis C drug  

NEW DELHI: Drug maker Hetero has received approval from DCGI to market generic version of Gilead's Harvoni, a drug used in the treatment of Hepatitis C, in the country.

Hetero is the first company in India to receive the approval for the fixed-dose combination Ledipasvir-Sofosbuvir (90mg/400mg) from Drug Controller General of India (DCGI), the company said in a statement.

Read more at:

No comments:

Post a Comment